Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Latrodectus antivenin - Instituto Bioclon/Rare Disease Therapeutics

Drug Profile

Latrodectus antivenin - Instituto Bioclon/Rare Disease Therapeutics

Alternative Names: Analatro; Antivenin Latrodectus equine immune F(ab)2 - RDT/Bioclon; Aracmyn; Black widow spider antivenin - RDT/Bioclon; Black widow spider antivenom - RDT/Bioclon; Latrodectus immune F(ab’)2 antivenom - Instituto Bioclon/Rare disease therapeutics; Spider venom antiserum - RDT/Bioclon

Latest Information Update: 07 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Instituto Bioclon
  • Developer Instituto Bioclon; Rare Disease Therapeutics
  • Class Antibodies; Antivenins
  • Mechanism of Action Spider venom inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spider venom poisoning
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Spider venom poisoning

Most Recent Events

  • 07 Dec 2018 Launched for Spider venom poisoning in USA before November 2018 (IV) (Rare disease therapeutics website, November 2018)
  • 12 Aug 2005 Phase-II clinical trials in Spider venom poisoning in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top